vitamin D supplementation in metabolic syndrome

Conditions

metabolic syndrome. metabolic disorders not specified

Aymaral Ghezel, Shabnam Salekzamani, Hossein Mehralizadeh, Mohammad Asghari Jafarabadi, Bahram Pourghassem Gargari

International Journal for Vitamin and Nutrition Research2019-03-043 citations

The effects of vitamin D supplementation on proatherogenic inflammatory markers and carotid intima media thickness in subjects with metabolic syndrome: a randomized double-blind placebo-controlled clinical trial.

Salekzamani S, Bavil AS, Mehralizadeh H, Jafarabadi MA, Ghezel A, Gargari BP.

2017-05-1632 citations

10.1007/s12020-017-1317-2

Effect of high-dose vitamin D supplementation on cardiometabolic risk factors in subjects with metabolic syndrome: a randomized controlled double-blind clinical trial.

Salekzamani S, Mehralizadeh H, Ghezel A, Salekzamani Y, Jafarabadi MA, Bavil AS, Gargari BP.

2016-07-1148 citations

10.1007/s40618-016-0507-8

Interventions

Intervention 1: Intervention: 50000 IU vitamin D3 every week for 4 months. Intervention 2: ?C??ontrol group: placebo.

Prevention

Placebo

Intervention: 50000 IU vitamin D3 every week for 4 months

?C??ontrol group: placebo

Eligibility

Sex/Gender

All

Age

30 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Willingness to participate; age 30–50 years; affected by metabolic syndrome with three out of five criteria: waist circumference>91 cm in women and >89 cm for men; serum triglyceride=150 mg/dL; fasting serum glucose=100mg/dL; serum HDL-C<40 mg/dL in men and <50 mg/dl in women; systolic blood pressure=130mmhg and/or diastolic blood pressure= 85mmhg. Exclusion criteria: being menopause; taking vitamin D, calcium, fish oil or other antioxidant supplements for at least 3 months preceding the study; taking anti lipid or anti-hypertensive drugs; smoking; current clinical disease like diabetes mellitus; cardiovascular disease; cancers; liver or kidney disease; any symptoms of inflammation or having surgery; parathyroid abnormalities; using corticosteroids, calcitonin, bisphosphonates for at least 3 months preceding the study; spiro or crohn disease; current diet therapy; pregnancy or lactation.

Exclusion criteria

Exclusion criteria:

Design outcomes

Secondary

Measure	Time frame
Serum inflammatory markers. Timepoint: baseline and 4 months after intervation. Method of measurement: ELISA.;Glycemic factors. Timepoint: baseline and 4 months after intervation. Method of measurement: enzymatic.;Lipid profiles. Timepoint: baseline and 4 months after intervation. Method of measurement: enzymatic colorimetric.;Blood pressure. Timepoint: baseline, 2 and 4 months after intervation. Method of measurement: digital sphygmomanometer.;Anthropometry markers. Timepoint: baseline , 2 and 4 months after intervation. Method of measurement: tape, scale, impedance analysis.	—

Measure

Time frame

Serum inflammatory markers. Timepoint: baseline and 4 months after intervation. Method of measurement: ELISA.;Glycemic factors. Timepoint: baseline and 4 months after intervation. Method of measurement: enzymatic.;Lipid profiles. Timepoint: baseline and 4 months after intervation. Method of measurement: enzymatic colorimetric.;Blood pressure. Timepoint: baseline, 2 and 4 months after intervation. Method of measurement: digital sphygmomanometer.;Anthropometry markers. Timepoint: baseline , 2 and 4 months after intervation. Method of measurement: tape, scale, impedance analysis.

—

Primary

Measure	Time frame
Serum 25-hydroxyvitamin vitamin D. Timepoint: befor and after intervention. Method of measurement: chemiluminescence immunoassay.;Carotid intima media thickness. Timepoint: baseline and 4 months after intervention. Method of measurement: ultrasonography.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShabnam Salekzamani

Faculty of Nutrition, Tabriz University pf Medical Sciences

salekzamanish@gmail.com+98 41 3335 7580

Outcome results

None listed